Continuous Glucose Monitoring for Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether real-time continuous glucose monitoring (rt-CGM) can reduce hospital readmissions for people with heart failure (HF) who also have diabetes. The researchers aim to determine if maintaining steady blood sugar levels, rather than checking them a few times a day, can improve heart health. Participants will use either a traditional blood sugar meter or the new rt-CGM device. Ideal participants are adults hospitalized for heart failure and managing diabetes with diet, pills, or insulin.
As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart health management for others with similar conditions.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications. However, it includes patients with diabetes treated with diet, oral antidiabetic agents, GLP1-RAs, or insulin, suggesting you may continue these treatments.
What prior data suggests that real-time continuous glucose monitoring is safe for heart failure patients?
Research has shown that real-time continuous glucose monitoring (rt-CGM) is generally safe for people with diabetes. Studies have found that rt-CGM can help reduce hospital visits for heart problems in this population, suggesting it could be a useful tool for managing both diabetes and heart-related issues.
However, some studies have noted that these devices might not always be accurate, particularly in critically ill patients after surgery. While the device is usually safe, its readings may not always be perfect in certain situations.
Overall, rt-CGM is well-tolerated, and many people with diabetes use it successfully to manage their blood sugar levels. This makes it a promising option for those with heart failure and diabetes who seek to improve their health.12345Why are researchers excited about this trial?
Researchers are excited about using Real-time Continuous Glucose Monitoring (rt-CGM) for heart failure patients because it provides continuous, real-time data on blood sugar levels, setting it apart from traditional glucose monitoring methods. Unlike standard care, which typically involves periodic fingerstick tests with a glucose meter, rt-CGM offers automatic readings and alerts for high or low blood sugar, allowing for more precise and timely adjustments to insulin therapy. This innovative approach could lead to better glucose control, potentially improving heart health and overall quality of life for patients with heart failure.
What evidence suggests that real-time continuous glucose monitoring is effective for heart failure?
Research has shown that real-time continuous glucose monitoring (rt-CGM) can significantly aid people with diabetes in managing their blood sugar levels. In this trial, participants in the CGM group will wear a Libre 2 rt-CGM, which provides immediate information and allows for quick treatment adjustments. Studies have found that using rt-CGM devices, like the Libre, is linked to a 78% decrease in hospital visits due to heart problems in people with diabetes. This is crucial because controlling blood sugar may lower the chances of returning to the hospital for heart issues. This technology could be especially beneficial for those with both diabetes and heart failure, as it helps maintain stable blood sugar levels and reduces the risk of serious complications.12367
Who Is on the Research Team?
Kasra Moazzami, MD, MPH
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
Adults aged 18 to 90 with acute decompensated heart failure (ADHF) and diabetes, treated with diet, oral antidiabetic agents, GLP1-RAs, or insulin. They must be experiencing NYHA class II-IV symptoms of heart failure.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Hospitalization and Initial Monitoring
Participants are monitored during their hospital stay using rt-CGM and POC glucose meters
Post-Discharge Monitoring
Participants are monitored for glycemic control and hypoglycemia events using rt-CGM for 12 weeks after discharge
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Real-time Continuous Glucose Monitoring (rt-CGM)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
American Heart Association
Collaborator
Abbott Diabetes Care
Industry Sponsor
Robert B. Ford
Abbott Diabetes Care
Chief Executive Officer since 2020
Bachelor's degree from Boston College, MBA from UC Berkeley, Haas School of Business
Dr. Mahmood Kazemi
Abbott Diabetes Care
Chief Medical Officer
Bachelor's and Master's degrees from Stanford University, MD from the University of California, San Francisco